ALT (Alternative Lengthening of Telomeres) cancers encompass a significant fraction (15%) of human cancers. These immortalized cells maintain their telomeres using homology-directed recombination. The observation that ALT is activated in a significant fraction of tumors, coupled with its potential as an adaptive mechanism to anti-telomerase tumor therapies, make it an important target for anti-cancer strategies. Yet, targetedtherapeuticsforALTcancershavenotbeengreatlyexplored.Recentstudiesshowedthatahallmark of ALT cells is loss of the chromatin remodeler ATRX, but how its loss contributes to telomere recombination had not been elucidated. We found that loss of ATRX suppresses resolution of sister chromatid cohesion at telomeres to promote sister telomere recombination and prevent deleterious non-allelic recombination. Sister telomere cohesion is normally resolved in G2/prophase of the cell cycle by the poly-ADP ribose polymerase tankyrase1thatlocalizestotelomeresthroughtheshelterinsubunitTRF1.WefoundthatduetolossofATRX the?normal?systemoftelomereresolutionisdefectiveinALTcellsandtelomeresremaincoheredintomitosis. IntheabsenceofATRXitsbindingpartner(thehistonevariantmacroH2A1.1)isfreetosequestertankyrase1, preventingit fromresolvingtelomerecohesion.Persistenttelomerecohesionhasanessentialrole,asforced resolutionoftelomerecohesionbyATRXintroductionortankyrase1overexpressioninALTcellsleadstoloss ofrecombinationbetweensistertelomeres,increasednon-sistercopying,andcelldeath.Wehypothesizethat persistenttelomerecohesionassistsintelomeremaintenancebypromotingsistertelomererecombinationand in safeguarding genome integrity by preventing aberrant and toxic non-sister recombination.
In Aim 1 of this proposal, I will elucidate the mechanisms of persistent telomere cohesion and in Aim 2, I will define the proteome of the cohered state in ALT cells. My studies will provide mechanistic insights into telomere recombinationandidentifypotentialtargetsforALTcancertherapy.

Public Health Relevance

PersistentsistertelomerecohesioninmitosisinALT(alternativelengtheningoftelomeres)tumorcellsis essentialfortelomererecombinationandcellgrowth.Understandingthemechanismandroleofthecohered telomerestateinALTcellswillprovidebasicinsightsintotelomererecombinationandidentifypotentialtargets foranti-ALTcancerstrategies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Predoctoral Individual National Research Service Award (F31)
Project #
5F31CA221162-03
Application #
9851876
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Radaev, Sergey
Project Start
2018-02-15
Project End
2021-02-14
Budget Start
2020-02-15
Budget End
2021-02-14
Support Year
3
Fiscal Year
2020
Total Cost
Indirect Cost
Name
New York University
Department
Pathology
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016